The gap between trailing and forward P/E points to a sharp expected normalization in reported earnings, consistent with the large non-operating swing seen in 2025Q4. The EV/EBITDA of 18.49 against a forward 11.59 implies the market is pricing in meaningful EBITDA growth, though the forward multiple still reflects a premium to a mature commercial-stage pharma peer set. Investors should monitor whether forward estimates hold, as the valuation case rests heavily on earnings stability that the historical quarters do not yet demonstrate.

The stable gross margin reflects a high-margin product mix, which is a structural strength. The operating margin swings, however, appear driven by the timing of commercial spending and R&D rather than by pricing or cost of goods, meaning the reported trend is a poor guide to run-rate earning power. Net margin further diverges from operating margin in several quarters, so the operating margin of recent quarters is the more defensible reference point for underlying profitability.

A ROIC in the mid-single digits remains modest for a company with a 90% gross margin, which indicates that the large equity base dilutes returns on capital deployed. The ROE trajectory is distorted by the single-quarter spike to 44.5% in 2025Q4, which reflects a one-off gain rather than an operating improvement. Investors should rely on ROIC rather than ROE when assessing capital efficiency, as the latter is materially inflated by non-recurring items.

Declining D/E reflects equity growth rather than debt repayment alone, so the improvement is partly a function of accumulated deficit reduction. The fall in interest coverage to 1.46 is the more important signal, as it indicates debt service capacity relative to operating earnings has tightened even as absolute leverage declined. Investors should monitor coverage given the volatility in quarterly operating income.

A current ratio above 6 indicates ample short-term asset coverage, but the sharp cash decline implies the composition of current assets, rather than their total, may be shifting. The quick ratio of 5.67 remains similarly high, which reduces concern about inventory dependence given the modest inventory days. Under severe stress, the cash balance would be the critical buffer, and its recent volatility warrants further investigation.